These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22894949)

  • 1. The "real world" barriers and solutions to Candida vaccine patent prosecutions: an analysis of U.S. Patent and Trademark Office actions on related applications.
    Wang SJ
    Hum Vaccin Immunother; 2012 Oct; 8(10):1443-9. PubMed ID: 22894949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida vaccines development from point view of US patent application.
    Wang SJ
    Hum Vaccin; 2011 Nov; 7(11):1165-71. PubMed ID: 22048114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
    Pillai X; Kinney WA
    Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The written description rejection as a barrier to biotech patent prosecution.
    Wang SJ
    Hum Vaccin; 2011 May; 7(5):569-73. PubMed ID: 21552000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.
    Lin F; Wang SJ
    Hum Vaccin Immunother; 2013 Nov; 9(11):2490-5. PubMed ID: 23899509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent first, ask questions later: morality and biotechnology in patent law.
    Bagley MA
    William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A brief guide to understanding patentability and the meaning of patents.
    Elliott GC
    Acad Med; 2002 Dec; 77(12 Pt 2):1309-14. PubMed ID: 12480641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The obviousness rejection as a barrier to vaccine patent prosecution.
    Wang SJ
    Hum Vaccin; 2011 Apr; 7(4):474-6. PubMed ID: 21808149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology and Protection of Intellectual Property: Emerging Trends.
    Siri JGS; Fernando CAN; De Silva SNT
    Recent Pat Nanotechnol; 2020; 14(4):307-327. PubMed ID: 32532198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design-around biotechnology patents: an analysis of US Federal Circuit decisions shows the possibility of designing around biotechnology patents.
    Wang SJ
    Hum Vaccin; 2011 Jan; 7(1):125-8. PubMed ID: 21263222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotechnological Patents Applications of the Deuterium Oxide in Human Health.
    da S Mariano RM; Bila WC; Trindade MJF; Lamounier JA; Galdino AS
    Recent Pat Biotechnol; 2017; 11(2):76-84. PubMed ID: 28078979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The road more traveled--common pitfalls on the way to a patent.
    Tu S; Wu B; Maebius S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(1):1-4. PubMed ID: 20803518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invisible genomes: the genomics revolution and patenting practice.
    Bostanci A; Calvert J
    Stud Hist Philos Biol Biomed Sci; 2008 Mar; 39(1):109-19. PubMed ID: 18331958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patents in Nanobiotechnology: A Cross Jurisdictional Approach.
    Manchikanti P; Uppala S; Bonta RK
    Recent Pat Biotechnol; 2017; 11(1):52-70. PubMed ID: 27881055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent strategies in molecular diversity.
    Green GD
    Mol Divers; 1997-1998; 3(4):247-52. PubMed ID: 9850521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is your reasonable expectation of success in obtaining pharmaceutical or biotechnology patents having nonobvious claimed inventions that the courts will uphold? An overview of obviousness court decisions.
    Pereira DJ; Kunin SG
    Cold Spring Harb Perspect Med; 2014 Dec; 5(4):. PubMed ID: 25475106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interfacing of Science, Medicine and Law: The Stem Cell Patent Controversy in the United States and the European Union.
    Davey S; Davey N; Gu Q; Xu N; Vatsa R; Devalaraja S; Harris P; Gannavaram S; Dave R; Chakrabarty A
    Front Cell Dev Biol; 2015; 3():71. PubMed ID: 26618158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the Bench to the Pharmacy: Protecting Innovation During Vaccine Development and Commercialization.
    Krol AC; Abu-Shaar M; Brady P
    Methods Mol Biol; 2016; 1404():813-834. PubMed ID: 27076339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of patent eligibility on biotech patents: A flow chart for determining patent eligibility and an immune therapy case study.
    Chang BC; Wang SJ
    Hum Vaccin Immunother; 2015; 11(3):789-94. PubMed ID: 25714661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digital pathology: A systematic evaluation of the patent landscape.
    Cucoranu IC; Parwani AV; Vepa S; Weinstein RS; Pantanowitz L
    J Pathol Inform; 2014; 5(1):16. PubMed ID: 25057430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.